<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:05:03Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10176680" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10176680</identifier>
        <datestamp>2023-05-13</datestamp>
        <setSpec>bmcneph</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id>
              <journal-title-group>
                <journal-title>BMC Nephrology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1471-2369</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10176680</article-id>
              <article-id pub-id-type="pmcid">PMC10176680</article-id>
              <article-id pub-id-type="pmc-uid">10176680</article-id>
              <article-id pub-id-type="pmid">37170244</article-id>
              <article-id pub-id-type="pmid">37170244</article-id>
              <article-id pub-id-type="publisher-id">3192</article-id>
              <article-id pub-id-type="doi">10.1186/s12882-023-03192-4</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Bradykinin B<sub>2</sub> receptor blockade and intradialytic hypotension</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Gamboa</surname>
                    <given-names>Jorge L.</given-names>
                  </name>
                  <address>
                    <email>jorge.gamboa@vanderbilt.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mambungu</surname>
                    <given-names>Cindy A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Clagett</surname>
                    <given-names>Adrienne R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nian</surname>
                    <given-names>Hui</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yu</surname>
                    <given-names>Chang</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ikizler</surname>
                    <given-names>T. Alp</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brown</surname>
                    <given-names>Nancy J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.412807.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9916</institution-id><institution>Department of Medicine, Division of Clinical Pharmacology, </institution><institution>Vanderbilt University Medical Center, </institution></institution-wrap>2222 Pierce Avenue 561B-PRB, Nashville, TN 37232-6602 USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.418356.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0478 7015</institution-id><institution>Veterans Administration Tennessee Valley Healthcare System, </institution></institution-wrap>Nashville, TN USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412807.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9916</institution-id><institution>Department of Medicine, Division of Nephrology and Hypertension, </institution><institution>Vanderbilt University Medical Center, </institution></institution-wrap>Nashville, TN USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.412807.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9916</institution-id><institution>Department of Biostatistics, </institution><institution>Vanderbilt University Medical Center, </institution></institution-wrap>Nashville, TN USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>11</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>11</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <volume>24</volume>
              <elocation-id>134</elocation-id>
              <history>
                <date date-type="received">
                  <day>17</day>
                  <month>5</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>30</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Introduction</title>
                  <p id="Par1">Intradialytic hypotension (IDH) is a common clinical complication and is associated with increased morbidity and mortality in patients undergoing maintenance hemodialysis (MHD). The pathogenesis of IDH has been attributed to the rapid reduction of plasma volume during hemodialysis and the inadequate compensatory mechanisms in response to hypovolemia, such as the lack of vasoconstriction. This may be due to the increased production of vasodilators, such as bradykinin. In this study we test the hypothesis that bradykinin B<sub>2</sub> receptor blockade prevents intradialytic hypotension.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">We performed a post-hoc analysis of a double-blind, placebo-controlled, randomized, 2 × 2 crossover clinical trial comparing the continuous infusion of icatibant, a bradykinin B<sub>2</sub> receptor blocker, and placebo during hemodialysis. Icatibant or placebo was infused for 30 min before and during hemodialysis in 11 patients on MHD.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">Seven of the patients had IDH, defined as a reduction of systolic blood pressure equal to or greater than 20 mmHg during hemodialysis. Stratified analysis, based on the presence of IDH, revealed that icatibant prevented the decrease in blood pressure compared to placebo in patients with IDH [blood pressure at average nadir (2.5 h after hemodialysis): Placebo,114.3 ± 8.9 vs. icatibant, 125.6 ± 9.1 mmHg, mean ± S.E.M]. Icatibant did not affect blood pressure in the group of patients without IDH.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p id="Par4">Bradykinin B2 receptor blocker may prevent the occurrence of IDH. Further studies should evaluate the hemodynamic effects of icatibant during hemodialysis and the symptomatology associated with IDH.</p>
                </sec>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1186/s12882-023-03192-4.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Bradykinin</kwd>
                <kwd>Hypotension</kwd>
                <kwd>Hemodialysis</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id>
                      <institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>K23DK100533</award-id>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000097</institution-id>
                      <institution>National Center for Research Resources</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1UL-1RR024975</award-id>
                  <award-id>1UL-1RR024975</award-id>
                  <award-id>1UL-1RR024975</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© BioMed Central Ltd., part of Springer Nature 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p id="Par9">Patients with end-stage kidney disease (ESKD) on maintenance hemodialysis (MHD) have a decreased life expectancy and increased mortality risk [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. A plethora of studies also suggests that hemodialysis-associated hemodynamic changes lead to significant adverse effects including patient-reported symptoms such as dizziness, cramps, and fatigue [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p>
              <p id="Par10">Intradialytic hypotension (IDH), a common clinical complication of hemodialysis, is defined as a decrease in systolic blood pressure (SBP) of 20 mmHg or more, and it is usually accompanied by symptoms such as cramps, dizziness, headache, and nausea [<xref ref-type="bibr" rid="CR5">5</xref>]. Approximately 75% of patients on MHD suffer at least one episode of hypotension during hemodialysis, [<xref ref-type="bibr" rid="CR6">6</xref>] and IDH occurs in approximately 20 to 30% of all regular hemodialysis treatments.[6;7] IDH is also associated with increased morbidity and mortality [<xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR12">12</xref>].</p>
              <p id="Par11">The pathogenesis of intradialytic hypotension has been attributed to the inappropriately rapid reduction of plasma volume during hemodialysis and the inadequate mechanisms to respond to hypovolemia in patients on MHD [<xref ref-type="bibr" rid="CR13">13</xref>]. The lack of compensatory vasoconstriction is one of the potential mechanisms associated with intradialytic hypotension. This inadequate response may be due to the removal of vasoconstrictors or the increased production of vasodilators. We and others have shown that hemodialysis induced the activation kallikrein-kinin system and the production of bradykinin [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Bradykinin may affect blood pressure during hemodialysis by inducing vasodilation through activation of the bradykinin B<sub>2</sub> receptor, [<xref ref-type="bibr" rid="CR16">16</xref>] and contributing to the pathogenesis of intradialytic hypotension.</p>
              <p id="Par12">In this study, we tested the hypothesis that blocking the B<sub>2</sub> receptor endogenous bradykinin prevents intradialytic hypotension, defined as a drop in systolic blood pressure equal to or greater than 20 mmHg. For this purpose, we conducted a post-hoc analysis of a double-blind, placebo-controlled, randomized, two by two crossover study comparing the effect of continuous infusion of the bradykinin B<sub>2</sub> receptor blocker icatibant, versus placebo on mitochondrial function during hemodialysis (primary outcome). Blood pressure was defined <italic>a priori</italic> as a secondary outcome of this clinical trial.</p>
            </sec>
            <sec id="Sec2" sec-type="materials|methods">
              <title>Materials and methods</title>
              <sec id="Sec3">
                <title>Study population</title>
                <p id="Par13">The study was approved by the Vanderbilt University Institutional Review Board and performed according to the Declaration of Helsinki. Two-hundred and two patients were pre-screened for eligibility, and 16 patients were approached and assessed for eligibility. Patients with a history of functional transplant less than six months prior to the study or anticipated live donor kidney transplant were excluded. Patients with a history of active connective tissue disease, acute infection within one month prior to the study, advanced liver disease, gastrointestinal dysfunction requiring parental nutrition, or active malignancy were not included in the study. Use of the following medications was also excluded: anti-inflammatory medication other than aspirin at a dose less than 325 mg per day, immunosuppressive drugs within one month prior to the study, vitamin E at a dose higher than 60 IU per day, or vitamin C at a dose higher than 500 mg per day. Subjects with a history of myocardial infarction or cerebrovascular event within three months prior to the study or with an ejection fraction lower than 40% were excluded. Other exclusion criteria were a history of ACEi-associated angioedema or cough, pregnancy, or breastfeeding. Three patients were excluded based on their inability to undergo magnetic resonance imaging (MRI). Thirteen patients provided written informed consent and agreed to participate in the study, but two withdrew from participation before any intervention. Therefore, 11 patients completed the study. Figure <xref rid="Fig1" ref-type="fig">1</xref> shows the flow diagram of patient enrollment. All participants had undergone adequate hemodialysis (Kt/V &gt; 1.2) thrice weekly for at least six consecutive months. Hemodialysis was performed using a Fresenius Optiflux 180 dialyzer (Fresenius Medical Care, Waltham, MA) with a polysulphone membrane. Dialysate quality was within the Association for the Advancement of Medical Instrumentation (AAMI) standards for endotoxin concentrations. In addition, hemodialysis was performed using Diasafe filters (Fresenius Medical Care), to ensure further purity of the dialysate. Patients were clinically stable with pre-hemodialysis potassium levels lower than 6.0 mmol/L.</p>
                <p id="Par14">
                  <fig id="Fig1">
                    <label>Fig. 1</label>
                    <caption>
                      <p>Flowchart of study participation and randomization</p>
                    </caption>
                    <graphic xlink:href="12882_2023_3192_Fig1_HTML" id="d32e438"/>
                  </fig>
                </p>
              </sec>
              <sec id="Sec4">
                <title>Study protocol</title>
                <p id="Par15">The study procedures were performed in the Vanderbilt University General Clinical Research Center (GCRC). Patients participated in a randomized placebo-controlled two by two crossover study, in which they received either, the bradykinin B<sub>2</sub> receptor blocker icatibant or placebo on the first study day. After a washout period of one week, participants returned to the Vanderbilt GCRC for the second study day to receive the other treatment (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Icatibant (30 mg) was diluted in 0.9% sodium chloride (NS) to a concentration of 100 ug/ ml. Icatibant or placebo (NS) was infused for 30 min prior to the initiation of hemodialysis at a rate of 100 µg/kg/h. The volume of infusion was the same on both study days. At the beginning of hemodialysis, the dose was changed to 50 µg/kg/h for the duration of hemodialysis. Previous studies have found that this dose of icatibant blocks the vasodilator effect and the tissue plasminogen activator release in response to infused bradykinin.[17;18] Subjects received their usual hemodialysis prescription, including the duration, for both study visits. Blood pressure was measured every 15 min during the duration of the study in the contralateral side of the arterial-venous access. Blood samples were collected from the arterial tubing of hemodialysis 30 min before hemodialysis, at the beginning of hemodialysis, 30 min and one hour after the initiation of hemodialysis, at the end of hemodialysis, and one hour after the end of hemodialysis. At the end of hemodialysis, patients remained in the GCRC for two hours; the last blood samples were collected.</p>
                <p id="Par16">
                  <fig id="Fig2">
                    <label>Fig. 2</label>
                    <caption>
                      <p>Study design. The study was a randomized, cross-over, double-blind, placebo-controlled study to study the effects of icatibant in mitochondrial function and blood pressure during hemodialysis</p>
                    </caption>
                    <graphic xlink:href="12882_2023_3192_Fig2_HTML" id="d32e461"/>
                  </fig>
                </p>
                <p id="Par17">Intradialytic hypotension was defined as a reduction of SBP equal to or greater than 20 mmHg during hemodialysis. We restricted the analysis of blood pressure to the first three hours of hemodialysis since the duration of hemodialysis varies from 3.25 to 4.5 h and most episodes of hypotension occurred during the first hour of hemodialysis.</p>
              </sec>
              <sec id="Sec5">
                <title>Laboratory procedures</title>
                <p id="Par18">For bradykinin measurements, blood was collected into polypropylene tubes containing chilled ethanol and let the mixture stand for 30 min at 4 °C. Samples were then centrifuged and the supernatant was stored frozen at -80 until processing. Bradykinin was measured by high-perfomance liquid chromatography (HPLC) following by electrospray inoisation mass spectrometry (ESI-MS) as previously described [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
              </sec>
              <sec id="Sec6">
                <title>Statistical methods</title>
                <p id="Par19">Data are presented as mean ± SEM or median and interquartile range. We also estimated the area under the curve for the change from baseline over time in blood pressure and heart rate, calculated by summing the numerical values of successive linear segments for every 15 min intervals. We used McNemar’s test to compare the occurrence of intradialytic hypotension between the treatment groups. The effect of treatment on blood pressure and heart rate were analyzed by comparing the areas under the curves with the Wilcoxon paired test.</p>
              </sec>
            </sec>
            <sec id="Sec7" sec-type="results">
              <title>Results</title>
              <sec id="Sec8">
                <title>Baseline patient characteristics</title>
                <p id="Par20">Baseline characteristics are shown in Table <xref rid="Tab1" ref-type="table">1</xref>. Causes of ESKD were hypertension (seven patients), lupus glomerulonephritis (one patient), immune-complex glomerulonephritis (one patient), focal segmental glomerulosclerosis (one patient), and chronic urinary tract obstruction due to posterior urethral valves (one patient).</p>
                <p id="Par21">
                  <table-wrap id="Tab1">
                    <label>Table 1</label>
                    <caption>
                      <p>Baseline characteristics</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th align="left" colspan="2">Parameter</th>
                          <th align="left">Value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>Age, (years)</bold>
                          </td>
                          <td align="left">44.73 ± 10.65</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>Gender, N male (%)</bold>
                          </td>
                          <td align="left">8/11 (72.7%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>Race, N African American (%)</bold>
                          </td>
                          <td align="left">8/11 (72.7%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>Smoker, N (%)</bold>
                          </td>
                          <td align="left">4/11 (36.4%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>BMI, kg/m</bold>
                            <sup>
                              <bold>2</bold>
                            </sup>
                          </td>
                          <td align="left">29.51 ± 7.90</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>History of hypertension, N (%)</bold>
                          </td>
                          <td align="left">11/11 (100%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>ACE inhibitor or ARB use, N (%)</bold>
                          </td>
                          <td align="left">1/11 (9%)</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>Glucose, mg/dL</bold>
                          </td>
                          <td align="left">86.91 ± 12.54</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>Creatinine, mg/dL</bold>
                          </td>
                          <td align="left">12.35 ± 4.30</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>Hemoglobin, %</bold>
                          </td>
                          <td align="left">11.50 ± 1.89</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>Albumin, g/dl</bold>
                          </td>
                          <td align="left">4.15 ± 0.39</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">
                            <bold>Calcium x phosphate product, mg</bold>
                            <sup>
                              <bold>2</bold>
                            </sup>
                            <bold>/dL</bold>
                            <sup>
                              <bold>2</bold>
                            </sup>
                          </td>
                          <td align="left">43.81 ± 13.48</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <p>ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. Data are presented as mean ± SD</p>
                    </table-wrap-foot>
                  </table-wrap>
                </p>
              </sec>
              <sec id="Sec9">
                <title>Effect of hemodialysis and bradykinin receptor blockade on blood pressure</title>
                <p id="Par22">Icatibant treatment did not affect blood pressure during hemodialysis compared to placebo treatment in the overall group (Figure <xref rid="MOESM1" ref-type="media">S1</xref>).</p>
                <p id="Par23">We next analyzed the effect of icatibant on blood pressure in patients with and without intradialytic hypotension.</p>
                <p id="Par24">The hemodialysis variables in patients with and without intradialytic hypotension are shown in Table <xref rid="Tab2" ref-type="table">2</xref>. In patients with intradialytic hypotension during placebo treatment, icatibant prevented the decrease in systolic blood pressure observed during placebo (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). There was a similar trend of icatibant on mean arterial blood pressure and diastolic blood pressure (Figure <xref rid="MOESM1" ref-type="media">S2</xref>). In addition, of the seven patients who developed intradialytic hypotension during the placebo administration, only one patient experienced hypotension during icatibant treatment (p = 0.031, Table <xref rid="Tab3" ref-type="table">3</xref>).</p>
                <p id="Par25">
                  <table-wrap id="Tab2">
                    <label>Table 2</label>
                    <caption>
                      <p>Hemodialysis variables in patients with and without intradialytic hypotension</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th align="left">Variables</th>
                          <th align="left">IDH<break/>(N = 7)</th>
                          <th align="left">No IDH<break/>(N = 4)</th>
                          <th align="left">p<break/>value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left">spKt/V</td>
                          <td align="left">1.51 ± 0.04</td>
                          <td align="left">1.48 ± 0.18</td>
                          <td char="." align="char">0.9</td>
                        </tr>
                        <tr>
                          <td align="left">Time of treatment (minutes)</td>
                          <td align="left">241.4 ± 33.8</td>
                          <td align="left">232.5 ± 8.7</td>
                          <td char="." align="char">0.5</td>
                        </tr>
                        <tr>
                          <td align="left">Specific ultrafiltration rate (ml/kg/h)</td>
                          <td align="left">9.80 ± 2.64</td>
                          <td align="left">9.81 ± 4.2</td>
                          <td char="." align="char">0.9</td>
                        </tr>
                        <tr>
                          <td align="left">Ultrafiltration volume</td>
                          <td align="left">3.68 ± 1.85</td>
                          <td align="left">2.70 ± 1.07</td>
                          <td char="." align="char">0.3</td>
                        </tr>
                        <tr>
                          <td align="left">Specific ultrafiltration volume (mL/kg)</td>
                          <td align="left">40.03 ± 14.51</td>
                          <td align="left">37.88 ± 15.70</td>
                          <td char="." align="char">0.8</td>
                        </tr>
                        <tr>
                          <td align="left">Ultrafiltration rate (L/h)</td>
                          <td align="left">0.88 ± 0.33</td>
                          <td align="left">0.70 ± 0.28</td>
                          <td char="." align="char">0.4</td>
                        </tr>
                        <tr>
                          <td align="left">Arteriovenous access type, N (%)</td>
                          <td align="left"/>
                          <td align="left"/>
                          <td align="left"/>
                        </tr>
                        <tr>
                          <td align="left">Fistula</td>
                          <td align="left">1 (86)</td>
                          <td align="left">2 (50)</td>
                          <td align="left"/>
                        </tr>
                        <tr>
                          <td align="left">Graft</td>
                          <td align="left">6 (14)</td>
                          <td align="left">1 (25)</td>
                          <td align="left"/>
                        </tr>
                        <tr>
                          <td align="left">Catheter</td>
                          <td align="left"/>
                          <td align="left">1 (25)</td>
                          <td align="left"/>
                        </tr>
                        <tr>
                          <td align="left">Dialysis vintage, months</td>
                          <td align="left">394 (103, 852)</td>
                          <td align="left">155 (43, 589)</td>
                          <td char="." align="char">0.2</td>
                        </tr>
                        <tr>
                          <td align="left">Medications, N (%)</td>
                          <td align="left"/>
                          <td align="left"/>
                          <td align="left"/>
                        </tr>
                        <tr>
                          <td align="left">ACEi/ARB</td>
                          <td align="left"/>
                          <td align="left">1 (25)</td>
                          <td align="left"/>
                        </tr>
                        <tr>
                          <td align="left">CCB</td>
                          <td align="left">2 (29)</td>
                          <td align="left">2 (50)</td>
                          <td align="left"/>
                        </tr>
                        <tr>
                          <td align="left">Beta-blockers</td>
                          <td align="left">2 (29)</td>
                          <td align="left">3 (75)</td>
                          <td align="left"/>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <p>Variables are expressed as mean ± SD, median (range), unless otherwise specified. IDH, intradialytic hypotension (decrease in systolic blood pressure equal to or greater than 20 mmHg). spKt/V, single pool Kt/V. ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers</p>
                    </table-wrap-foot>
                  </table-wrap>
                </p>
                <p id="Par26">
                  <fig id="Fig3">
                    <label>Fig. 3</label>
                    <caption>
                      <p>Effect of icatibant on systolic blood pressure (SBP) during hemodialysis in patients with a reduction of blood pressure ≥ 20 mmHg (n = 7). <bold>A.</bold> SBP was monitored every 15 min before and during hemodialysis. <bold>B</bold> and <bold>C</bold>, change in blood pressure from baseline and area under the curve showing that icatibant prevented the reduction in blood pressure during hemodialysis</p>
                    </caption>
                    <graphic xlink:href="12882_2023_3192_Fig3_HTML" id="d32e907"/>
                  </fig>
                </p>
                <p id="Par29">
                  <fig id="Fig4">
                    <label>Fig. 4</label>
                    <caption>
                      <p>Effect of icatibant on heart rate during hemodialysis in patients without (n = 4, A) and with (n = 7, B) intradialytic hypotension (IDH, a reduction of blood pressure ≥ 20 mmHg). Heart rate was measured every 15 min before and during hemodialysis</p>
                    </caption>
                    <graphic xlink:href="12882_2023_3192_Fig4_HTML" id="d32e919"/>
                  </fig>
                </p>
                <p id="Par27">
                  <table-wrap id="Tab3">
                    <label>Table 3</label>
                    <caption>
                      <p>Episodes of intradialytic hypotension during icatibant and placebo treatments</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <th align="left" colspan="2"/>
                          <th align="left">IDH</th>
                          <th align="left">No IDH</th>
                          <th align="left" colspan="1"/>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" colspan="2">Placebo</td>
                          <td align="left">7</td>
                          <td align="left">4</td>
                          <td align="left" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" colspan="2">Icatibant</td>
                          <td align="left">1</td>
                          <td align="left">10</td>
                          <td align="left" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <p>IDH, intradialytic hypotension (decrease in systolic blood pressure equal to or greater than 20 mmHg).</p>
                    </table-wrap-foot>
                  </table-wrap>
                </p>
                <p id="Par28">Icatibant did not affect heart rate during hemodialysis in patients with intradialytic hypotension (Fig. <xref rid="Fig4" ref-type="fig">4</xref>), although the change in heart rate change over the first 30 min after the initiation of hemodialysis was greater in patients with intradialytic hypotension than in patients without (1.9 ± 1.6 versus − 7.0 ± 4.4, p = 0.02). Icatibant did not affect blood pressure in patients without intradialytic hypotension.</p>
              </sec>
              <sec id="Sec10">
                <title>Effect of icatibant on bradykinin concentrations</title>
                <p id="Par30">Bradykinin concentrations were measured prior to, at the beginning of hemodialysis, at 30, and 60 min after initiation of hemodialysis. There was no effect of icatibant versus placebo on bradykinin levels during hemodialysis. In addition, patients who experienced intradialytic hypotension had similar bradykinin levels compared to patients who did not experience hypotension [80.9 (37.5, 104.8) vs. 85.9 (45.0, 155.1) fmol/ml, median (interquartile range), at 30 min, p = 0.66].</p>
              </sec>
              <sec id="Sec11">
                <title>Adverse events</title>
                <p id="Par31">There was no adverse event related to the study intervention. Three patients delevop symptoms associated with hypotension. All of them reported cramps and one of them also complain of dizziness.</p>
              </sec>
            </sec>
            <sec id="Sec12" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par32">In this pilot study, we found that bradykinin B<sub>2</sub> receptor blockade with icatibant during hemodialysis prevents intradialytic hypotension, suggesting that endogenous bradykinin contributes to intradialytic hypotension. While we are not able to define the primary mechanism, our findings suggest that interfering with the vasodilatory effect of bradykinin during hemodialysis could be useful in those patients with a predisposition to intradialytic hypotension.</p>
              <p id="Par33">The lack of vasoconstriction in response to hypovolemia is one of the impaired responses during intradialytic hypotension. Previous studies suggest that vasopressin, nitric oxide, and adenosine are associated with the occurrence of intradialytic hypotension [<xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR25">25</xref>]. A recent study also showed that blockade of adenosine A<sub>1</sub> receptor may prevent the occurrence of hypotension during hemodialysis [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
              <p id="Par34">Bradykinin is a potent vasoactive peptide that results from the cleavage of high molecular kininogen by tissue and plasma kallikreins and causes vasodilation through the activation of the bradykinin B<sub>2</sub> receptor [<xref ref-type="bibr" rid="CR16">16</xref>]. Hemodialysis increases bradykinin levels by activating the kallikrein-kinin cascade and the contact system [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Bradykinin is also increased during cardiopulmonary bypass surgery and contributes to the hypotensive response to protamine [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Similar to our results in patients undergoing hemodialysis, icatibant attenuates these hypotensive events during cardiopulmonary bypass [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
              <p id="Par35">Intradialytic hypotension is a common clinical complication of hemodialysis, and it is associated with increased morbidity and mortality [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. It has been shown that intradialytic hypotension may induce myocardial dysfunction due to reduced myocardial blood flow [<xref ref-type="bibr" rid="CR12">12</xref>]. Recurrent episodes of hypotension are also associated with frontal lobe atrophy in the brain, [<xref ref-type="bibr" rid="CR8">8</xref>] and with mesenteric ischemia [<xref ref-type="bibr" rid="CR32">32</xref>]. Intradialytic hypotension is also associated with common patient-reported symptoms, particularly dizziness and cramps [<xref ref-type="bibr" rid="CR3">3</xref>]. Furthermore, intradialytic hypotension and a higher specific ultrafiltration rate have been associated with longer hemodialysis recovery time, [<xref ref-type="bibr" rid="CR33">33</xref>] a measure of quality of life (QOL) that has been validated in patients on hemodialysis that correlates well with longer and more complex QOL questionnaires [<xref ref-type="bibr" rid="CR34">34</xref>]. Thus, future studies should evaluate the effect of icatibant not only in blood pressure during hemodialysis but also on alleviating the associated patient-reported outcomes.</p>
              <p id="Par36">Bradykinin usually peaks within the first 15 min of hemodialysis, [<xref ref-type="bibr" rid="CR14">14</xref>] which may explain why we did not observe an increase in bradykinin levels during hemodialysis. This may also explain why we did not detect a difference in bradykinin levels between patients who experienced intradialytic hypotension and patients who do not develop hypotension. Another explanation may reside in individual genetic susceptibility to bradykinin. It has been shown that a particular genetic polymorphism of the bradykinin B<sub>2</sub> receptor gene (BE1) is associated with bradykinin-induced vasodilation [<xref ref-type="bibr" rid="CR35">35</xref>]. This susceptibility may also explain the lack of effect of icatibant on blood pressure in patients without intradialytic hypotension. Future studies should evaluate the relationship between polymorphisms of the bradykinin B<sub>2</sub> receptor gene and the risk of intradialytic hypotension.</p>
              <p id="Par37">We have not measured the clearance of icatibant by the dialyzer, however, vitamin B12 has similar biophysical properties compared to icatibant, such as molecular weight and water solubility. In this study, the KoA (dialyzer mass transfer area coefficient) for vitamin B12 was 312 ml/min (at blood and dialysate flow of 300 and 500 mL/min, respectively). Thus, some amount of icatibant may be cleared during hemodialysis and limit its effectiveness. For this reason, icatibant was continuously infused before and during hemodialysis. Nevertheless, further studies should evaluate the clearance of icatibant during hemodialysis.</p>
              <p id="Par38">This study has some limitations: First, our study should be considered exploratory since our inclusion criteria did not specifically select patients with a documented history of hemodialysis-induced hypotension, and the primary objective of the study was to study mitochondrial function and blood pressure during hemodialysis, but not intradialytic hypotension. While our results are intriguing, future studies should target patients with a history of dialysis-induced hypotension to confirm our findings. Second, this study included young, predominantly male, and African American patients. Thus, the results of the study may not be generalized to a more diverse population of patients on hemodialysis. There were also numerous exclusion criteria that may limit the generalization of the results. Finally, while we used a cross-over design, our sample size is relatively small, and our results should be interpreted with caution.</p>
              <p id="Par39">In conclusion, our study suggests that endogenous bradykinin contributes to the decrease in blood pressure during hemodialysis. Pharmacological therapies that block the effect of bradykinin or inhibit the activation of the kallikrein-kinin system, such as the ones approved for use in hereditary angioedema, represent potential novel treatments for the prevention of intradialytic hypotension.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Electronic supplementary material</title>
              <sec id="Sec13">
                <p>Below is the link to the electronic supplementary material.</p>
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="12882_2023_3192_MOESM1_ESM.pdf">
                      <caption>
                        <p>Supplementary Material 1</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher’s Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We would to thankc Patricia Wright, Anthony Dematteo, and Shouzuo Wei for their valuable technical assistant. We also like to thank all the participants for their dedication to the study.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Authors’ contributions</title>
              <p>The study design was contributed by JLG, NJB, and TAI. The formal analysis was contributed by JLG, HN, and CY. Writing the original draft was contributed by JLG, NJB, TAI. Experiment and data acquisition were contributed by JLG, CM, and AC. Writing and editing the manuscript were contributed by JLG, CM, AC, HN, CY, TAI, and NJB. All the authors approved the final version of the manuscript.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This study is supported in part by 1UL-1RR024975 and K23DK100533 grants from the National Institutes of Health, and drug supply through Investigator-Initiated Research Support (IIR-USA-000344 from Shire/Takeda). The sponsors did not influence the design, execution, and analysis of the results of the study.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data Availability</title>
              <p>The data that support the findings of this study are included in the article and supplementary material. Further inquiries can be directed to the corresponding author.</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1">
                <title>Ethics approval and consent to participate</title>
                <p id="Par40">All the study participants had given written informed consent before enrollment. Prior to the initiation of the study, we obtained approval from Vanderbilt Institutional Review Board (IRB #131602). This study was conducted in accordance with the Declaration of Helsinsky.</p>
              </notes>
              <notes id="FPar2">
                <title>Consent for publication</title>
                <p id="Par41">Not applicable.</p>
              </notes>
              <notes id="FPar3" notes-type="COI-statement">
                <title>Competing interests</title>
                <p id="Par42">Shire/Takeda provided icatibant for the study through an Investigator Initiated Research Support grant. Drs. Brown and Gamboa serve as consultants to Pharvaris. Dr. Brown serves on the scientific advisory board for Alnylam Pharmaceuticals. The remaining authors have declared no conflict of interests.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Foley</surname>
                      <given-names>RN</given-names>
                    </name>
                    <name>
                      <surname>Parfrey</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Sarnak</surname>
                      <given-names>MJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Epidemiology of cardiovascular disease in chronic renal disease</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>1998</year>
                  <volume>9</volume>
                  <fpage>16</fpage>
                  <lpage>S23</lpage>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sarnak</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Andrew</surname>
                      <given-names>SLevey</given-names>
                    </name>
                  </person-group>
                  <article-title>Epidemiology of Cardiac Disease in Dialysis Patients</article-title>
                  <source>Semin Dial</source>
                  <year>1999</year>
                  <volume>12</volume>
                  <fpage>69</fpage>
                  <lpage>76</lpage>
                  <pub-id pub-id-type="doi">10.1046/j.1525-139X.1999.00006.x</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meredith</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Pugh</surname>
                      <given-names>CW</given-names>
                    </name>
                    <name>
                      <surname>Sutherland</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tarassenko</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Birks</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>The relationship between symptoms and blood pressure during maintenance hemodialysis</article-title>
                  <source>Hemodial Int</source>
                  <year>2015</year>
                  <volume>19</volume>
                  <fpage>543</fpage>
                  <lpage>52</lpage>
                  <pub-id pub-id-type="doi">10.1111/hdi.12306</pub-id>
                  <?supplied-pmid 25952255?>
                  <pub-id pub-id-type="pmid">25952255</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kuipers</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Oosterhuis</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Krijnen</surname>
                      <given-names>WP</given-names>
                    </name>
                    <name>
                      <surname>Dasselaar</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Gaillard</surname>
                      <given-names>CAJM</given-names>
                    </name>
                    <name>
                      <surname>Westerhuis</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Franssen</surname>
                      <given-names>CFM</given-names>
                    </name>
                  </person-group>
                  <article-title>Prevalence of intradialytic hypotension, clinical symptoms and nursing interventions - a three-months, prospective study of 3818 haemodialysis sessions</article-title>
                  <source>BMC Nephrol</source>
                  <year>2016</year>
                  <volume>17</volume>
                  <fpage>21</fpage>
                  <pub-id pub-id-type="doi">10.1186/s12882-016-0231-9</pub-id>
                  <?supplied-pmid 26922795?>
                  <pub-id pub-id-type="pmid">26922795</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chou</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Kalantar-Zadeh</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Mathew</surname>
                      <given-names>AT</given-names>
                    </name>
                  </person-group>
                  <article-title>A brief review of intradialytic hypotension with a focus on survival</article-title>
                  <source>Semin Dial</source>
                  <year>2017</year>
                  <volume>30</volume>
                  <fpage>473</fpage>
                  <lpage>80</lpage>
                  <pub-id pub-id-type="doi">10.1111/sdi.12627</pub-id>
                  <?supplied-pmid 28661565?>
                  <pub-id pub-id-type="pmid">28661565</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sands</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Usvyat</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Sullivan</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Segal</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Zabetakis</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kotanko</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Maddux</surname>
                      <given-names>FW</given-names>
                    </name>
                    <name>
                      <surname>Diaz-Buxo</surname>
                      <given-names>JA</given-names>
                    </name>
                  </person-group>
                  <article-title>Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome</article-title>
                  <source>Hemodial Int</source>
                  <year>2014</year>
                  <volume>18</volume>
                  <fpage>415</fpage>
                  <lpage>22</lpage>
                  <pub-id pub-id-type="doi">10.1111/hdi.12138</pub-id>
                  <?supplied-pmid 24467830?>
                  <pub-id pub-id-type="pmid">24467830</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Palmer</surname>
                      <given-names>BF</given-names>
                    </name>
                    <name>
                      <surname>Henrich</surname>
                      <given-names>WL</given-names>
                    </name>
                  </person-group>
                  <article-title>Recent advances in the Prevention and Management of Intradialytic Hypotension</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2008</year>
                  <volume>19</volume>
                  <fpage>8</fpage>
                  <lpage>11</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2007091006</pub-id>
                  <?supplied-pmid 18178796?>
                  <pub-id pub-id-type="pmid">18178796</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mizumasa</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Hirakata</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Yoshimitsu</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Hirakata</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kubo</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kashiwagi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tanaka</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Kanai</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Fujimi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Iida</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Dialysis-related hypotension as a cause of Progressive Frontal Lobe Atrophy in Chronic Hemodialysis Patients: a 3-Year prospective study</article-title>
                  <source>Nephron Clin Pract</source>
                  <year>2004</year>
                  <volume>97</volume>
                  <fpage>c23</fpage>
                  <lpage>c30</lpage>
                  <pub-id pub-id-type="doi">10.1159/000077592</pub-id>
                  <?supplied-pmid 15153764?>
                  <pub-id pub-id-type="pmid">15153764</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shoji</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Tsubakihara</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Fujii</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Imai</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients</article-title>
                  <source>Kidney Int</source>
                  <year>2004</year>
                  <volume>66</volume>
                  <fpage>1212</fpage>
                  <lpage>20</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00812.x</pub-id>
                  <?supplied-pmid 15327420?>
                  <pub-id pub-id-type="pmid">15327420</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tislér</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Akócsi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Borbás</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Fazakas</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Ferenczi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Gõrõgh</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kulcsár</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Nagy</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Sámik</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Szegedi</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Tóth</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Wágner</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Kiss</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis</article-title>
                  <source>ndt</source>
                  <year>2003</year>
                  <volume>18</volume>
                  <fpage>2601</fpage>
                  <lpage>5</lpage>
                  <?supplied-pmid 14605284?>
                  <pub-id pub-id-type="pmid">14605284</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Flythe</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Xue</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Lynch</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Curhan</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Brunelli</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Association of Mortality Risk with various definitions of Intradialytic Hypotension</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2015</year>
                  <volume>26</volume>
                  <fpage>724</fpage>
                  <lpage>34</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2014020222</pub-id>
                  <?supplied-pmid 25270068?>
                  <pub-id pub-id-type="pmid">25270068</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McIntyre</surname>
                      <given-names>CW</given-names>
                    </name>
                    <name>
                      <surname>Burton</surname>
                      <given-names>JO</given-names>
                    </name>
                    <name>
                      <surname>Selby</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Leccisotti</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Korsheed</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Baker</surname>
                      <given-names>CSR</given-names>
                    </name>
                    <name>
                      <surname>Camici</surname>
                      <given-names>PG</given-names>
                    </name>
                  </person-group>
                  <article-title>Hemodialysis-Induced Cardiac Dysfunction is Associated with an Acute reduction in Global and Segmental Myocardial Blood Flow</article-title>
                  <source>Clin J Am Soc Nephrol</source>
                  <year>2008</year>
                  <volume>3</volume>
                  <fpage>19</fpage>
                  <lpage>26</lpage>
                  <pub-id pub-id-type="doi">10.2215/CJN.03170707</pub-id>
                  <?supplied-pmid 18003765?>
                  <pub-id pub-id-type="pmid">18003765</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <mixed-citation publication-type="other">Reeves PB, Mc Causland FR. Mechanisms, Clinical Implications, and Treatment of Intradialytic Hypotension. Clin J Am Soc Nephrol 2018.</mixed-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Renaux</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Crost</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Loughraieb</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Vantard</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH</article-title>
                  <source>Kidney Int</source>
                  <year>1999</year>
                  <volume>55</volume>
                  <fpage>1097</fpage>
                  <lpage>103</lpage>
                  <pub-id pub-id-type="doi">10.1046/j.1523-1755.1999.0550031097.x</pub-id>
                  <?supplied-pmid 10027949?>
                  <pub-id pub-id-type="pmid">10027949</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gamboa</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Pretorius</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Todd-Tzanetos</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Luther</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Ikizler</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>NJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparative Effects of Angiotensin-Converting enzyme inhibition and angiotensin-receptor blockade on inflammation during Hemodialysis</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2012</year>
                  <volume>23</volume>
                  <fpage>334</fpage>
                  <lpage>42</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2011030287</pub-id>
                  <?supplied-pmid 22158433?>
                  <pub-id pub-id-type="pmid">22158433</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vanhoutte</surname>
                      <given-names>PM</given-names>
                    </name>
                  </person-group>
                  <article-title>Endothelium and control of vascular function</article-title>
                  <source>State of the Art lecture Hypertension</source>
                  <year>1989</year>
                  <volume>13</volume>
                  <fpage>658</fpage>
                  <lpage>67</lpage>
                  <?supplied-pmid 2661425?>
                  <pub-id pub-id-type="pmid">2661425</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brown</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Gainer</surname>
                      <given-names>JV</given-names>
                    </name>
                    <name>
                      <surname>Murphey</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Vaughan</surname>
                      <given-names>DE</given-names>
                    </name>
                  </person-group>
                  <article-title>Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B<sub>2</sub> receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway</article-title>
                  <source>Circulation</source>
                  <year>2000</year>
                  <volume>102</volume>
                  <fpage>2190</fpage>
                  <lpage>6</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.CIR.102.18.2190</pub-id>
                  <?supplied-pmid 11056091?>
                  <pub-id pub-id-type="pmid">11056091</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cockcroft</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Chowienczyk</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Brett</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Bender</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Ritter</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist</article-title>
                  <source>Br J Clin Pharmacol</source>
                  <year>1994</year>
                  <volume>38</volume>
                  <fpage>317</fpage>
                  <lpage>21</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2125.1994.tb04360.x</pub-id>
                  <?supplied-pmid 7833220?>
                  <pub-id pub-id-type="pmid">7833220</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murphey</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Hachey</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Oates</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Morrow</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>NJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Metabolism of bradykinin in vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite</article-title>
                  <source>J Pharmacol Exp Ther</source>
                  <year>2000</year>
                  <volume>294</volume>
                  <fpage>263</fpage>
                  <?supplied-pmid 10871321?>
                  <pub-id pub-id-type="pmid">10871321</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ettema</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Zittema</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Kuipers</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gansevoort</surname>
                      <given-names>RT</given-names>
                    </name>
                    <name>
                      <surname>Vart</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>de Jong</surname>
                      <given-names>PE</given-names>
                    </name>
                    <name>
                      <surname>Westerhuis</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Franssen</surname>
                      <given-names>CFM</given-names>
                    </name>
                  </person-group>
                  <article-title>Dialysis Hypotension: a role for inadequate increase in arginine vasopressin levels? A systematic literature review and Meta-analysis</article-title>
                  <source>Am J Nephrol</source>
                  <year>2014</year>
                  <volume>39</volume>
                  <fpage>100</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1159/000358203</pub-id>
                  <?supplied-pmid 24503523?>
                  <pub-id pub-id-type="pmid">24503523</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Raj</surname>
                      <given-names>DSC</given-names>
                    </name>
                    <name>
                      <surname>Vincent</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Simpson</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sato</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Welbourne</surname>
                      <given-names>TC</given-names>
                    </name>
                    <name>
                      <surname>Levi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Shah</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Blandon</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Zager</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Robbins</surname>
                      <given-names>RA</given-names>
                    </name>
                  </person-group>
                  <article-title>Hemodynamic changes during hemodialysis: role of nitric oxide and endothelin</article-title>
                  <source>Kidney Int</source>
                  <year>2002</year>
                  <volume>61</volume>
                  <fpage>697</fpage>
                  <lpage>704</lpage>
                  <pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00150.x</pub-id>
                  <?supplied-pmid 11849413?>
                  <pub-id pub-id-type="pmid">11849413</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yokokawa</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Mankus</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Saklayen</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Kohno</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Yasunari</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Minami</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kano</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Horio</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Takeda</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Mandel</surname>
                      <given-names>AK</given-names>
                    </name>
                  </person-group>
                  <article-title>Increased nitric oxide production in patients with hypotension during Hemodialysis</article-title>
                  <source>Ann Intern Med</source>
                  <year>1995</year>
                  <volume>123</volume>
                  <fpage>35</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="doi">10.7326/0003-4819-123-1-199507010-00005</pub-id>
                  <?supplied-pmid 7762912?>
                  <pub-id pub-id-type="pmid">7762912</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chang</surname>
                      <given-names>CT</given-names>
                    </name>
                    <name>
                      <surname>Chien</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>Hsu</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>IK</given-names>
                    </name>
                    <name>
                      <surname>Lim</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>CC</given-names>
                    </name>
                  </person-group>
                  <article-title>Nitric oxide production and blood pressure reduction during haemodialysis</article-title>
                  <source>Nephrology</source>
                  <year>2014</year>
                  <volume>19</volume>
                  <fpage>562</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="doi">10.1111/nep.12280</pub-id>
                  <?supplied-pmid 24839907?>
                  <pub-id pub-id-type="pmid">24839907</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moylan</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Westfall</surname>
                      <given-names>TC</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of adenosine on adrenergic neurotransmission in the superfused rat portal vein</article-title>
                  <source>Blood Vessels</source>
                  <year>1979</year>
                  <volume>16</volume>
                  <fpage>302</fpage>
                  <lpage>10</lpage>
                  <?supplied-pmid 230871?>
                  <pub-id pub-id-type="pmid">230871</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Daugirdas</surname>
                      <given-names>JT</given-names>
                    </name>
                  </person-group>
                  <article-title>Pathophysiology of dialysis hypotension: an update</article-title>
                  <source>Am J Kidney Dis</source>
                  <year>2001</year>
                  <volume>38</volume>
                  <fpage>11</fpage>
                  <lpage>S17</lpage>
                  <pub-id pub-id-type="doi">10.1053/ajkd.2001.28090</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Imai</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Fujii</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kohno</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Kageyama</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Nakahara</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Hori</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tsubakihara</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Adenosine A1 receptor antagonist improves intradialytic hypotension</article-title>
                  <source>Kidney Int</source>
                  <year>2006</year>
                  <volume>69</volume>
                  <fpage>877</fpage>
                  <lpage>83</lpage>
                  <pub-id pub-id-type="doi">10.1038/sj.ki.5000088</pub-id>
                  <?supplied-pmid 16395260?>
                  <pub-id pub-id-type="pmid">16395260</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Maat</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>de Groot</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Maas</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Contact System activation on endothelial cells</article-title>
                  <source>Semin Thromb Hemost</source>
                  <year>2014</year>
                  <volume>40</volume>
                  <fpage>887</fpage>
                  <lpage>94</lpage>
                  <pub-id pub-id-type="doi">10.1055/s-0034-1395159</pub-id>
                  <?supplied-pmid 25389102?>
                  <pub-id pub-id-type="pmid">25389102</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cugno</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Nussberger</surname>
                      <given-names>P</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Alamanni</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Coppola</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Agostoni</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion</article-title>
                  <source>Chest</source>
                  <year>2001</year>
                  <volume>120</volume>
                  <fpage>1776</fpage>
                  <lpage>82</lpage>
                  <pub-id pub-id-type="doi">10.1378/chest.120.6.1776</pub-id>
                  <?supplied-pmid 11742901?>
                  <pub-id pub-id-type="pmid">11742901</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pretorius</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Scholl</surname>
                      <given-names>FG</given-names>
                    </name>
                    <name>
                      <surname>McFarlane</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Murphey</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>NJ</given-names>
                    </name>
                  </person-group>
                  <article-title>A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass</article-title>
                  <source>Clin Pharmacol Ther</source>
                  <year>2005</year>
                  <volume>78</volume>
                  <fpage>477</fpage>
                  <lpage>85</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.clpt.2005.08.010</pub-id>
                  <?supplied-pmid 16321614?>
                  <pub-id pub-id-type="pmid">16321614</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stefánsson</surname>
                      <given-names>BV</given-names>
                    </name>
                    <name>
                      <surname>Brunelli</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Cabrera</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Rosenbaum</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Anum</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Ramakrishnan</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Jensen</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>St+Ñlhammar</surname>
                      <given-names>NO</given-names>
                    </name>
                  </person-group>
                  <article-title>Intradialytic hypotension and risk of Cardiovascular Disease</article-title>
                  <source>Clin J Am Soc Nephrol</source>
                  <year>2014</year>
                  <volume>9</volume>
                  <fpage>2124</fpage>
                  <pub-id pub-id-type="doi">10.2215/CJN.02680314</pub-id>
                  <?supplied-pmid 25376764?>
                  <pub-id pub-id-type="pmid">25376764</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chou</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Streja</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Nguyen</surname>
                      <given-names>DV</given-names>
                    </name>
                    <name>
                      <surname>Rhee</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Obi</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Inrig</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Amin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kovesy</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Sim</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Kalantar-Zadeh</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients</article-title>
                  <source>ndt</source>
                  <year>2018</year>
                  <volume>33</volume>
                  <fpage>149</fpage>
                  <lpage>59</lpage>
                  <?supplied-pmid 28444336?>
                  <pub-id pub-id-type="pmid">28444336</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Seong</surname>
                      <given-names>EY</given-names>
                    </name>
                    <name>
                      <surname>Zheng</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Winkelmayer</surname>
                      <given-names>WC</given-names>
                    </name>
                    <name>
                      <surname>Montez-Rath</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>TI</given-names>
                    </name>
                  </person-group>
                  <article-title>The relationship between Intradialytic Hypotension and hospitalized mesenteric ischemia</article-title>
                  <source>Clin J Am Soc Nephrol</source>
                  <year>2018</year>
                  <volume>13</volume>
                  <fpage>1517</fpage>
                  <pub-id pub-id-type="doi">10.2215/CJN.13891217</pub-id>
                  <?supplied-pmid 30237215?>
                  <pub-id pub-id-type="pmid">30237215</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hussein</surname>
                      <given-names>WF</given-names>
                    </name>
                    <name>
                      <surname>Arramreddy</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Reiterman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schiller</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Higher Ultrafiltration Rate is Associated with longer Dialysis Recovery Time in Patients undergoing conventional hemodialysis</article-title>
                  <source>Am J Nephrol</source>
                  <year>2017</year>
                  <volume>46</volume>
                  <fpage>3</fpage>
                  <lpage>10</lpage>
                  <pub-id pub-id-type="doi">10.1159/000476076</pub-id>
                  <?supplied-pmid 28554180?>
                  <pub-id pub-id-type="pmid">28554180</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lindsay</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Heidenheim</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Nesrallah</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Garg</surname>
                      <given-names>AX</given-names>
                    </name>
                    <name>
                      <surname>Suri</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Minutes to Recovery after a Hemodialysis Session: a simple health-related quality of Life question that is Reliable, Valid, and sensitive to change</article-title>
                  <source>Clin J Am Soc Nephrol</source>
                  <year>2006</year>
                  <volume>1</volume>
                  <fpage>952</fpage>
                  <pub-id pub-id-type="doi">10.2215/CJN.00040106</pub-id>
                  <?supplied-pmid 17699312?>
                  <pub-id pub-id-type="pmid">17699312</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van Guilder</surname>
                      <given-names>GP</given-names>
                    </name>
                    <name>
                      <surname>Pretorius</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Luther</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Byrd</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Hill</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Gainer</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent Vasodilation during angiotensin-converting enzyme inhibition</article-title>
                  <source>Hypertension</source>
                  <year>2008</year>
                  <volume>51</volume>
                  <fpage>454</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.107.102574</pub-id>
                  <?supplied-pmid 18180402?>
                  <pub-id pub-id-type="pmid">18180402</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
